Newer cervical cancer test no better than the old?
Posted on: Friday, 13 January 2006, 10:25 CST
NEW YORK (Reuters Health) - Findings from a review of published studies suggest that the newer liquid-based cervical cancer tests are no better than the conventional Pap test for checking for signs of cervical cancer. However, definitive research in this area is lacking, so the authors are calling for large randomized controlled trials.
Developed as an alternative to the traditional Pap smear, liquid-based "cytology" uses a thin layer of cells that yields results faster than the Pap test and is thought to be more sensitive than the Pap smear. The newer tests are also believed to generate fewer unsatisfactory slide results. While some countries have adopted liquid-based cytology as a screening method, controversy regarding its benefits persists.
In a review of 56 studies, including more than one million slides, that looked at liquid-based and conventional cytology, Dr. Elizabeth Davey, from the University of Sydney in Australia, and colleagues found little differences in the two approaches.
They report in the Lancet this week that the liquid-based tests did not detect any more serious cervical lesions, which could lead to cancer, than the conventional tests. Liquid-based and conventional cytology also produced a similar number of unsatisfactory slides.
However, only four studies had sufficient data to determine the sensitivity and specificity of both types of cytology, suggesting, the researchers conclude, that much more study is needed before firm conclusions can be drawn.
SOURCE: The Lancet January 14, 2006.
Source: REUTERS
Related Articles
- HPV testing followed by cytology and repeat HPV testing may improve cervical cancer screening
- Get the Facts About Genetic Testing for Cancer
- Oncolab Outlines Applications for AMAS Antibody Test for Cancer As a Chronic Disease at NAAS Conference in San Antonio
- Combo May Help Cancer Patients ; Study Says Chemo, Drug Aid Survival
- Protox to Test Prostate-Cancer Drug in Texas
- Noninvasive Tests May Miss Breast Cancer, AHRQ Study Finds
- Conventional Tests Miss Heart Disease in Millions of Women
- Vitamin D lowers cancer risk: study
- Altus Pharmaceuticals Announces Completion of Clinical Testing in the Phase I Study of ALTU-238 - a Long-Acting Crystalline Formulation of Human Growth Hormone
- Breast Cancer Prevention Study Spotlights Debate Over Drug Trials
User Comments (0)

RSS Feeds